Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBITDA (2020 - 2025)

Lyell Immunopharma's EBITDA history spans 6 years, with the latest figure at -$38.7 million for Q3 2025.

  • For Q3 2025, EBITDA rose 10.88% year-over-year to -$38.7 million; the TTM value through Sep 2025 reached -$326.2 million, down 61.46%, while the annual FY2024 figure was -$342.6 million, 50.84% down from the prior year.
  • EBITDA for Q3 2025 was -$38.7 million at Lyell Immunopharma, up from -$42.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$6.0 million in Q4 2022 and bottomed at -$192.4 million in Q4 2024.
  • The 5-year median for EBITDA is -$52.3 million (2025), against an average of -$60.2 million.
  • The largest annual shift saw EBITDA soared 92.96% in 2022 before it plummeted 764.05% in 2023.
  • A 5-year view of EBITDA shows it stood at -$85.3 million in 2021, then skyrocketed by 92.96% to -$6.0 million in 2022, then plummeted by 764.05% to -$51.8 million in 2023, then crashed by 271.13% to -$192.4 million in 2024, then soared by 79.89% to -$38.7 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's EBITDA are -$38.7 million (Q3 2025), -$42.8 million (Q2 2025), and -$52.3 million (Q1 2025).